Recorded on December 4, 2024                             Pricing: Free for Members and Non-Members

Please note that this session is not accredited for continuing pharmacy education credit.

Program Description

AMD is a degenerative eye disease and is a leading cause of irreversible vision loss especially in developed countries. The global prevalence of AMD is expected to increase to 288 million by 2040 and the US prevalence to increase to 22 million by 2050. The two main types of AMD are the dry and wet forms. Dry AMD is the most common type, accounting for approximately 80% of all cases, while the less common wet AMD accounts for 90% of severe vision loss (20/200 or worse). In those over the age of 40, AMD accounts for 46% of cases of severe vision loss (20/200 or worse).

DR is an eye condition that can cause vision loss and blindness in diabetic patients. It most often affects the retinal blood vessels. People with type 1, type 2, and gestational diabetes can all develop diabetic retinopathy. The risk for DR increases the longer you have diabetes. More than one half of diabetics will develop DR, and patients can lessen their risk of developing DR by controlling their diabetes. Early diabetic retinopathy may initially be asymptomatic but finding it early upon eye examination may help patients protect their vision. Diabetic retinopathy is the most common cause of vision loss, but patients are also more likely to develop cataracts, open-angle glaucoma, diabetic macular edema (DME), and retinal detachment.

This webinar will describe the disease state of nAMD and DR. A brief overview of the current treatment regimens will be presented. Real world data on Anti-VEGF therapy will be examined along with their limitations. An explanation of gene therapy currently under study and the mechanism of action will be provided. A description of the routes of administration for gene therapy in nAMD and DR will be explained.

Learning Objectives

• Review the clinical efficacy and safety of current treatment options for nAMD and DR.
• Describe the real-world limitations of current treatment regimens available for patients.
• Recognize the potential advantages of gene therapy in nAMD and DR.

This webinar is sponsored, developed, and presented by the sponsor. The content of this Science & Innovation Webinar and opinions expressed by the presenters are those of the sponsor or presenters and not of AMCP.

Sponsored by:

For individuals from the media/press interested in attending, please email media@amcp.org.